It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
How does SARS-CoV-2 cause lung microenvironment disturbance and inflammatory storm is still obscure. We here performed the single-cell transcriptome sequencing from lung, blood, and bone marrow of two dead COVID-19 patients and detected the cellular communication among them. Our results demonstrated that SARS-CoV-2 infection increase the frequency of cellular communication between alveolar type I cells (AT1) or alveolar type II cells (AT2) and myeloid cells triggering immune activation and inflammation microenvironment and then induce the disorder of fibroblasts, club, and ciliated cells, which may cause increased pulmonary fibrosis and mucus accumulation. Further study showed that the increase of T cells in the lungs may be mainly recruited by myeloid cells through ligands/receptors (e.g., ANXA1/FPR1, C5AR1/RPS19, and CCL5/CCR1). Interestingly, we also found that certain ligands/receptors (e.g., ANXA1/FPR1, CD74/COPA, CXCLs/CXCRs, ALOX5/ALOX5AP, CCL5/CCR1) are significantly activated and shared among lungs, blood and bone marrow of COVID-19 patients, implying that the dysregulation of ligands/receptors may lead to immune cell’s activation, migration, and the inflammatory storm in different tissues of COVID-19 patients. Collectively, our study revealed a possible mechanism by which the disorder of cell communication caused by SARS-CoV-2 infection results in the lung inflammatory microenvironment and systemic immune responses across tissues in COVID-19 patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Jinling Hospital, Nanjing University School of Medicine, Institute of Laboratory Medicine, Nanjing, China (GRID:grid.440259.e) (ISNI:0000 0001 0115 7868); Nanjing Normal University, Laboratory for Comparative Genomics and Bioinformatics, College of Life Science, Nanjing, China (GRID:grid.260474.3) (ISNI:0000 0001 0089 5711)
2 Southwest Hospital, Third Military Medical University (Army Medical University), Institute of Pathology, Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China (GRID:grid.416208.9) (ISNI:0000 0004 1757 2259); Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.416208.9)
3 Jinling Hospital, Nanjing University School of Medicine, Institute of Laboratory Medicine, Nanjing, China (GRID:grid.440259.e) (ISNI:0000 0001 0115 7868)
4 Nanjing Normal University, Laboratory for Comparative Genomics and Bioinformatics, College of Life Science, Nanjing, China (GRID:grid.260474.3) (ISNI:0000 0001 0089 5711)
5 Jinling Hospital, Nanjing University School of Medicine, Institute of Laboratory Medicine, Nanjing, China (GRID:grid.440259.e) (ISNI:0000 0001 0115 7868); Nanjing University School of Medicine, Department of Gastroenterology, Jinling Hospital, Nanjing, China (GRID:grid.41156.37) (ISNI:0000 0001 2314 964X)
6 Jinling Hospital, Nanjing University School of Medicine, Institute of Laboratory Medicine, Nanjing, China (GRID:grid.440259.e) (ISNI:0000 0001 0115 7868); Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e)
7 Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e); Medical Technical Support Division, the 904th Hospital, Changzhou, China (GRID:grid.440259.e)
8 Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e); Daping Hospital, Third Military Medical University (Army Medical University), Department of Gastroenterology, Chongqing, China (GRID:grid.410570.7) (ISNI:0000 0004 1760 6682)
9 Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e); Department of Laboratory Medicine and Blood Transfusion, the 907th Hospital, Fujian, China (GRID:grid.440259.e)
10 Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e); Chinese PLA Center for Disease Control and Prevention, Beijing, China (GRID:grid.488137.1) (ISNI:0000 0001 2267 2324)
11 Pulmonary and Critical Care Medicine, Yancheng No.1 People’s Hospital, Yancheng, China (GRID:grid.440259.e)
12 Wuhan Huoshenshan Hospital, Joint Expert Group for COVID-19, Department of Laboratory Medicine & Blood Transfusion, Wuhan, China (GRID:grid.440259.e); 920 Hospital of the Joint Service Support Force of the Chinese People’s Liberation Army, Department of Laboratory Medicine, Kunming, China (GRID:grid.440259.e)